administering to [a] <u>said</u> mammal, prior to tissue transplantation, a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 prevents complement-mediated cytotoxicity in said mammal.

3. (Amended) A method of ameliorating [an immune-mediated disorder] <u>complement-mediated cytotoxicity in a mammal</u> which comprises

identifying a mammal at risk of developing complement-mediated cytotoxicity; and administering, at the time of tissue transplantation, a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 prevents complement-mediated cytotoxicity in said mammal.

6. (Amended) A method of treating [an immune-mediated disorder] <u>complement-mediated cytotoxicity in a mammal</u> which comprises

identifying a mammal with complement-mediated cytotoxicity and administering to [a] said mammal [experiencing said immune-mediated disorder] a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 prevents complement-mediated cytotoxicity in said mammal.

Add the following new claims:

-110. The method of claim 1 wherein said mammal is a human.

 $\alpha^2$ 

11. The method of claim 6 wherein said mammal is a human.

- 12. The method of claim 1 wherein said mammal has necrotic injury.
- 13. A method of treating necrotic injury in a mammal comprising identifying a mammal with necrotic injury; and administering to said mammal a therapeutically effective amount of interleukin-11.
- 14. The method of claim 13, wherein said mammal is a human.
- 15. The method of claim 13, wherein administering IL-11 is due to localized tissue or cell injury.
- 16. The method of claim 13, wherein said necrotic injury is caused by loss of blood supply, corrosion, burning, or local lesion of a disease.
- 17. The method of claim 14, wherein administering IL-11 is due to localized tissue or cell injury.
- 18. The method of claim 14, wherein said necrotic injury is cased by loss of blood supply, corrosion, burning, or local lesion of a disease.
- 19. The method of claim 13, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100  $\mu$ g/kg body weight.